Announcements Trials
Browse Landscape

Phase

Phase 1 2

Status

Completed 2Withdrawn 1Terminated 1

Sponsor Class

OTHER 1INDUSTRY 1

Study Type

Interventional 2

Sponsor

Cancer Type

Gastrointestinal 2

Conditions

Pancreatic Neoplasms 16Neoplasms 4Colorectal Neoplasms 3Adenocarcinoma 3Pancreatic Cancer Metastatic 2Neoplasm Metastasis 2Pancreatic Cancer Non-resectable 1Diabetes Mellitus, Insulin-Dependent, 12 1Cholangiocarcinoma 1Carcinoma 1

Interventions

Gemcitabine 74Capecitabine 60Paclitaxel 59Fluorouracil 58Oxaliplatin 57Bevacizumab 51Docetaxel 50Leucovorin 48Nivolumab 40Cisplatin 40Irinotecan 39Carboplatin 37Cetuximab 34pembrolizumab 32Radiosurgery 32Trastuzumab 30Radiotherapy 27Everolimus 24Sorafenib 23Pemetrexed 20Doxorubicin 20Albumin-Bound Paclitaxel 20Ipilimumab 19Cyclophosphamide 19Panitumumab 18Zoledronic Acid 17Lapatinib 17Erlotinib Hydrochloride 17Prednisone 16pazopanib 15

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Completed × Neoplasm Metastasis × folfirinox × Clear all
NCT04990037 2023-06-29

CAPAFOUR

Cantargia AB

Phase 1 Completed
25 enrolled
Gastrointestinal

Adenocarcinoma, Carcinoma, Neoplasm Metastasis, Pancreatic Neoplasms

NCT01485744 2020-08-04

LDE225 With Fluorouracil, Leucovorin, Oxaliplatin, and Irinotecan for Untreated Advanced Pancreatic Cancer

Massachusetts General Hospital

Phase 1 Completed
39 enrolled
Gastrointestinal

Neoplasm Metastasis, Pancreatic Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡